Guardant Health, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Helmy Eltoukhy
- Full Time Employees
- 2,506
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 3100 Hanover Street Palo Alto CA United States of America 94063
- IPO Date
- Oct 4, 2018
- CIK
- 0001576280
- Website
- guardanthealth.com
- Similar Companies
- Business
- Guardant Health, Inc. is a precision oncology company specializing in blood and tissue-based diagnostic tests, real-world data sets, and AI-driven analytics to enhance cancer detection, treatment, and patient care. Founded in 2012 and headquartered in Palo Alto, California, the company provides a comprehensive portfolio of products including Guardant360 Liquid Biopsy tests (Guardant360, Guardant360 CDx, Guardant360 TissueNext, Guardant360 Response), Guardant Infinity, Guardant Reveal for early-stage cancer, the Shield test for colorectal cancer screening, and GuardantOMNI for biopharmaceutical research. It also offers integrated software solutions like Guardant Connect and research platforms such as Guardant INFORM and Guardant Galaxy. Guardant serves oncology patients, clinicians, and biopharmaceutical companies across the United States and internationally, including direct operations in Asia, the Middle East, and Africa following its full acquisition of Guardant Health AMEA which expanded its reach to 41 countries in those regions. Recent major developments include a strategic multi-year collaboration with Pfizer to leverage Guardant's liquid biopsy technology in global clinical trials and therapeutic development, including access to the Chinese market. The company has advanced its Smart Liquid Biopsy platform with expanded Medicare coverage, notably for its Guardant Reveal and Shield tests, facilitating broader adoption for cancer surveillance and screening. Guardant also completed the full acquisition of Guardant Health AMEA from SoftBank, consolidating its global operations to accelerate market penetration in high cancer burden regions. In 2024, Guardant reported record revenue growth driven by increased reimbursement and volume for Guardant360 assays, and it continues to innovate with new offerings for early detection and therapy response monitoring in multiple cancer indications. This positions Guardant Health as a leading biotechnology firm in precision oncology diagnostics and data analytics worldwide.
Artisan Mid Cap Fund Q2 2026 Performance Review
ISCG vs. RZG: Which Small-Cap Growth ETF Is the Better Buy for Investors?
Guardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026
The Surprising Reason Guardant Health, A Top 3% Stock, Soared To A Five-Year High
Which Small Cap ETF Is the Better Buy in 2026? iShares and JPMorgan Have Compelling Offerings
UnitedHealth Group Now Covers Guardant Health's Shield Blood Test for Colorectal Cancer Screening
State Street SPDR Small Cap ETF Outpaces iShares on Returns
Living Longer Is Big Business. These Stocks Will Benefit.
Gamehost Receives Final Court Order Authorizing Sale to Pure Casino Entertainment
Gamehost Shareholders Approve Sale to Pure Casino Entertainment
Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim's HERNEXEOS®
Here's Why This Colon Cancer Testing Biotech Is A Mutual Fund Favorite
Here Are Tuesday’s Top Wall Street Analyst Research Calls: CoreWeave, Danaher, Hewlett Packard Enterprise, Intuit, Knight-Swift, Meta Platforms, Starwood Property Trust, Tripadvisor, and More
Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting
Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting
Guardant Health Is Poised To Break Out At The Open — Here's Why It Surged
American Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening Guidelines
American Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening Guidelines
Guardant Health Secures FDA Approval For Expanded Liquid Biopsy Test
Guardant Health Leaps On A Major Win In Cancer Detection; Will Shares Break Out?